Kiora Pharmaceuticals Inc (KPRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.76 (+3.37%), Market cap $0.01B, 52-week low–high $1.80 ~ $3.90.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-10
Financial statements, price targets, institutional (13F) holdings and related news for Kiora Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Kiora Pharmaceuticals Inc trades at $2.76 (+3.37%). Real-time quotes and charts are available on BlackAll Trade.
Kiora Pharmaceuticals Inc has a market cap of about $0.01B.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product